Follicular Lymphoma - Market Insight, Epidemiology, and Market Forecast - 2036
Description
Key Highlights
The Follicular Lymphoma Market Report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM Follicular Lymphoma Market Size from 2022 to 2036. The report also covers Follicular Lymphoma Treatment practices and unmet medical needs to curate the best opportunities and assess the market’s potential.
Key Factors Driving the Follicular Lymphoma Market
Follicular Lymphoma incidence fueling market growth
Follicular Lymphoma, the most common indolent NHL subtype, accounts for about 20–22% of cases. In 2024, an estimated 35K cases were diagnosed in the 7MM, with females higher at 18K. Cases are expected to rise by 2034 due to aging populations, better diagnostics, and longer survival, expanding the market and increasing demand for new treatments.
Follicular Lymphoma Follicular Lymphoma treatment paradigm
Current FL treatment mainly involves rituximab-based immunochemotherapy, radioimmunotherapy (e.g., ibritumomab tiuxetan), and targeted agents like PI3K inhibitors and CAR-T therapies in relapsed cases. Approved therapies include GAZYVA, TAZVERIK, EPKINLY/TEPKINLY, LUNSUMIO, YESCARTA, BREYANZI, KYMRIAH, BRUKINSA, ORDSPONO, and RITUXAN HYCELA.
Follicular Lymphoma pipeline spotlight
The Follicular Lymphoma pipeline is robust, featuring bispecific antibodies, next-generation ADCs, and off-the-shelf CAR constructs designed to achieve deeper, more durable remissions with better tolerability. Key pipeline therapies include MONJUVI, AZD0486, Golcadomide, Abexinostat, NKTR-255, CTX112, IMPT-314, and others. Leading companies driving these developments are Roche, Gilead/Kite, Novartis, AstraZeneca, BeiGene, Regeneron, and MEI Pharma. In January 2025, CRISPR Therapeutics announced plans to engage regulators on CTX112 for B-cell malignancies, with updates expected mid-2025. These advances build upon established treatments that define the current standard of care.
Follicular Lymphoma Market Dynamics and Opportunity
Adoption of newer therapies will hinge on demonstrating superior survival and quality-of-life benefits versus standard immunochemotherapy, balanced against cost, toxicity profile, and payer restrictions—defining the competitive commercial outlook of the Follicular Lymphoma market.
Follicular Lymphoma Disease Understanding
Follicular Lymphoma Overview
Follicular lymphoma is usually a slow-growing, indolent B-cell lymphoproliferative disorder that originates from transformed follicular center B cells. It often presents with widespread lymph node enlargement, bone marrow involvement, and an enlarged spleen, while involvement of organs outside the lymphatic system is less frequent. Low blood cell counts are relatively common, but systemic symptoms such as fever, night sweats, and weight loss are rare unless the disease transforms into diffuse large B-cell lymphoma. Follicular lymphoma is generally considered a chronic condition rather than a curable one.
Further details are provided in the report…
Follicular Lymphoma Diagnosis
The diagnosis of follicular lymphoma relies on examining tissue obtained from a lymph node or other affected site. An incisional biopsy is generally preferred over a needle biopsy to ensure enough tissue is available for grading and evaluating potential transformation. Immunohistochemical analysis typically shows positive staining for cell surface markers CD19, CD20, CD10, and monoclonal immunoglobulin, along with cytoplasmic bcl-2 protein. Most cases also exhibit the t(14;18) chromosomal translocation involving the IgH and bcl-2 genes. Imaging with CT scans of the chest, abdomen, and pelvis can identify abdominal or pelvic lymph node involvement, while PET scans may be helpful in selected scenarios, such as localized disease or suspected transformation. Bone marrow aspiration and chromosomal analysis can further support the diagnosis, as the t(14;18) translocation is present in the majority of patients with follicular lymphoma.
Further details related to country-based variations are provided in the report…
Follicular Lymphoma Treatment
Treatment approaches for follicular lymphoma depend on the disease stage. For patients who are asymptomatic with low tumor burden and no cytopenias, a “watch and wait” strategy is often appropriate, as early intervention with chemotherapy or single-agent rituximab has not shown an overall survival benefit. Patients who require treatment are generally managed with chemoimmunotherapy, which has been shown to improve response rates, response duration, and overall survival. Maintenance therapy with rituximab has demonstrated additional advantages in randomized trials. In front-line settings, lenalidomide was found to be non-inferior to chemoimmunotherapy and, in relapsed cases, combining lenalidomide with rituximab outperformed rituximab alone. Other options for relapsed disease include kinase inhibitors, stem cell transplantation (SCT), and chimeric antigen receptor T-cell (CAR-T) therapy. For early-stage, localized disease, radiation therapy or surgical excision may be considered in select patients.
Follicular Lymphoma Epidemiology
The Follicular Lymphoma epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Incidence Cases, Gender-specific Cases, Age-specific Cases, Stage Specific Cases, Grade Specific Cases, and Treated Cases by Line of therapy of Follicular lymphoma in the United States, EU4 countries (Germany, France, Italy, Spain) and the United Kingdom, and Japan from 2022 to 2036.
Key Findings from Follicular Lymphoma Epidemiological Analyses and Forecast
A few key players are leading the treatment landscape of Follicular Lymphoma, such as Incyte Corporation, AstraZeneca, Bristol Myers Squibb, Xynomic Pharmaceuticals, and others. The details of the country-wise and therapy-wise market size have been provided below.
The section dedicated to drugs in the Follicular Lymphoma report provides an in-depth evaluation of late-stage pipeline drugs (Phase III) related to Follicular Lymphoma. The drug chapters section provides valuable information on various aspects related to clinical trials of Follicular Lymphoma, such as the pharmacological mechanisms of the drugs involved, designations, approval status, patent information, and a comprehensive analysis of the pros and cons associated with each drug. Furthermore, it presents the most recent news updates and press releases on drugs targeting Follicular Lymphoma.
Follicular Lymphoma Marketed Drugs
LUNSUMIO (mosunetuzumab): Roche
LUNSUMIO (mosunetuzumab) is a bispecific antibody therapy developed for adults with relapsed or refractory (R/R) follicular lymphoma who have undergone two or more previous treatments. It functions by binding simultaneously to T cells and B cells, triggering the immune system to attack and eliminate cancerous B cells. However, it may also impact healthy cells. The most notable risk is Cytokine Release Syndrome (CRS), a potentially serious and life-threatening side effect. Its safety and effectiveness in children have not been established.
In December 2024, Chugai received regulatory approval in Japan for intravenous administration of LUNSUMIO, allowing its use as monotherapy for patients who have received at least two prior therapies—a key step forward in treating R/R follicular lymphoma. Previously, in December 2022, the FDA granted accelerated approval for LUNSUMIO in adults with R/R follicular lymphoma after two or more systemic therapies. Additionally, in June 2022, Roche announced that the European Commission granted conditional marketing authorization for LUNSUMIO to treat adults with R/R follicular lymphoma who had previously received at least two systemic therapies.
BRUKINSA (zanubrutinib): BeiGene
BRUKINSA (zanubrutinib) is a small-molecule Bruton's tyrosine kinase (BTK) inhibitor approved for use in adult patients with relapsed or refractory (r/r) follicular lymphoma, in combination with obinutuzumab, following two or more prior systemic therapies. It is the first and only BTK inhibitor specifically approved for follicular lymphoma. Zanubrutinib works by irreversibly binding to BTK, blocking B-cell signaling pathways that drive B-cell proliferation, adhesion, and migration, thereby helping to slow tumor growth.
In March 2024, the FDA granted accelerated approval for BRUKINSA with obinutuzumab for adults with r/r follicular lymphoma after at least two prior systemic treatments. Earlier, in August 2022, the drug received orphan-drug designation from the FDA for the treatment of follicular lymphoma.
Follicular Lymphoma Emerging Therapies
MONJUVI (tafasitamab): Incyte Corporation
MONJUVI (tafasitamab) is a humanized, Fc-engineered monoclonal antibody that targets CD19 on B-cells. By binding to CD19, it inhibits its function and induces B-cell destruction. In 2010, MorphoSys obtained exclusive global rights to develop and commercialize tafasitamab from Xencor, Inc. The antibody’s XmAb-modified Fc domain promotes B-cell killing through apoptosis and immune-mediated mechanisms, including Antibody-Dependent Cell-mediated Cytotoxicity (ADCC) and Antibody-Dependent Cellular Phagocytosis (ADCP).
In December 2024, Incyte presented late-breaking results at the ASH Annual Meeting from the pivotal Phase III inMIND trial. The study showed that MONJUVI (tafasitamab), when combined with lenalidomide and rituximab, significantly improved progression-free survival (PFS) in patients with relapsed or refractory follicular lymphoma, achieving both the primary endpoint of PFS and key secondary endpoints.
AZD0486: AstraZeneca
AZD0486 (previously TNB-486) is a novel, fully human IgG4 CD19xCD3 bispecific T-cell engager (TCE) that features a unique low-affinity anti-CD3 component designed to minimize cytokine release while maintaining strong T-cell–mediated killing of malignant B cells. Its silenced Fc region prevents nonspecific binding and antibody-dependent cellular cytotoxicity, and provides a long half-life that supports intermittent dosing. The drug is currently in Phase III development for treating follicular lymphoma.
In November 2024, at ASH 2024, AstraZeneca showcased the strength of its hematology portfolio with two oral presentations on AZD0486. Phase I data demonstrated encouraging efficacy in patients with relapsed/refractory follicular lymphoma, showing a 96% overall response rate (ORR) and 85% complete response rate (CRR) at doses of 2.4 mg and higher.
Follicular Lymphoma Market Outlook
Frontline treatment for follicular lymphoma is well established, with most patients achieving durable responses to chemoimmunotherapy (CIT). For localized disease, radiotherapy (RT) alone or combined with immunochemotherapy is commonly used, and RT alone may also be appropriate for relapsed localized cases.
The treatment landscape for follicular lymphoma is diverse and continues to evolve, offering multiple options for both frontline and relapsed/refractory (R/R) disease. Among the cornerstone therapies is GAZYVA/GAZYVARO (obinutuzumab), which, when combined with chemotherapy, has become a standard in frontline management and demonstrates efficacy in both untreated and relapsed patients. Similarly, RITUXAN (rituximab) and its combination form RITUXAN HYCELA remain widely used, particularly in relapsed cases. The availability of generic rituximab has further enhanced accessibility and cost-effectiveness, maintaining its key role in treatment.
Targeted therapies are also expanding options. TAZVERIK (tazemetostat), an EZH2 inhibitor, offers a precision medicine approach for patients with specific mutations, while BRUKINSA (ibrutinib), a Bruton's tyrosine kinase inhibitor, contributes to therapy in selected follicular lymphoma cases. The recent approvals of EPKINLY/TEPKINLY (epcoritamab), a bispecific antibody targeting CD3 and CD20, alongside CAR T-cell therapies including KYMRIAH (tisagenlecleucel), LUNSUMIO (mosunetuzumab), YESCARTA (axicabtagene ciloleucel), and BREYANZI (lisocabtagene maraleucel), are ushering in a new era of immunotherapy. These innovative treatments are demonstrating promising results, particularly in R/R disease, and have the potential to provide longer-lasting remissions.
Overall, a wide range of effective therapies is already available for follicular lymphoma, with ongoing research likely to introduce further advancements. During the 2026–2036 forecast period, emerging treatments are expected to enhance existing options, while rising global healthcare spending may improve access to more effective and affordable therapies for patients.
Latest KOL Views on Follicular Lymphoma
To stay abreast of the latest trends in the market, we conduct primary research by seeking the opinions of Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) who work in the relevant field. This helps us fill any gaps in data and validate our secondary research.
We have reached out to industry experts to gather insights on various aspects of Follicular Lymphoma, including the evolving treatment landscape, patients’ reliance on conventional therapies, their acceptance of therapy switching, drug uptake, and challenges related to accessibility. The experts we contacted included medical/scientific writers, professors, and researchers from prestigious universities in the US, Europe, the UK, and Japan.
Our team of analysts at Delveinsight connected with more than 15 KOLs across the 7MM. We contacted institutions. By obtaining the opinions of these experts, we gained a better understanding of the current and emerging treatment patterns in the Follicular Lymphoma market, which will assist our clients in analyzing the overall epidemiology and market scenario.
Follicular Lymphoma Report Qualitative Analysis
We perform Qualitative and Market Intelligence analysis using various approaches, such as SWOT analysis and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst’s discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.
Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, designation, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy. In efficacy, the trial’s primary and secondary outcome measures are evaluated; for instance, in trials for Follicular Lymphoma, one of the most important primary endpoints was achieving Maximum tolerated dose, PFS, Incidence of AEs, OR, and others.
Further, the therapies’ safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.
Follicular Lymphoma Market Access and Reimbursement
Follicular lymphoma, also known as follicle center lymphoma or nodular lymphoma, is a common type of non-Hodgkin’s lymphoma, a slow-growing cancer, which affects the body’s immune system. It may appear in your lymph nodes, bone marrow, or other organs. In January 2024, the PAN Foundation announced to opening of a new follicular lymphoma fund, providing up to USD 4,600 per year to help eligible patients pay for out-of-pocket deductible, copay, and coinsurance costs.
The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.
Follicular Lymphoma Market Report Insights
- The Follicular Lymphoma Market Size in the 7MM is expected to grow from USD 1,702 million in 2025 to USD 3,081 million in 2036.
- The Follicular Lymphoma Market is projected to grow at a CAGR of 6.8% by 2036 in leading countries like the US, EU4, UK, and Japan.
- Follicular lymphoma is an indolent variety of non-Hodgkin’s lymphoma (NHL) originating from germinal center B cells. Follicular lymphoma is one of the most prevalent forms of indolent B cell NHL. It has a long disease course due to the chronic incurable nature of the disease in the majority of patients.
- Morphological assessment of a lymph node excisional biopsy is crucial for diagnosing follicular lymphoma. Lymph nodes will show variable-sized, closely packed follicles containing small cleaved cells without nucleoli (centrocytes) and larger noncleaved cells with moderate cytoplasm, open chromatin, and multiple nucleoli (centroblasts).
- Approved therapies for follicular lymphoma include GAZYVA, TAZVERIK, EPKINLY/ TEPKINLY, LUNSUMIO, YESCARTA, BREYANZI, KYMRIAH, BRUKINSA, ORDSPONO, and RITUXAN HYCELA.
- In February 2025, Regeneron Pharmaceuticals announced that it had resubmitted the Biologics License Application (BLA) for odronextamab in relapsed/refractory follicular lymphoma to the FDA. The company anticipates a decision from the FDA by the second half of 2025.
- In 2024, there are a total of ~35,000 diagnosed cases of follicular lymphoma across the 7MM.
- In 2024, females represented the highest number of cases in the 7MM, with ~18,000 cases.
- In 2024, the United States accounted for the largest market share for follicular lymphoma in the 7MM, with approximately USD 1,000 million.
- Numerous drugs are currently in development for the treatment of follicular lymphoma, including promising therapies like MONJUVI (tafasitamab), AZD0486, Golcadomide, Abexinostat, NKTR-255, CTX112, IMPT-314, and others, which are set to launch in the 7MM during the forecast period (2026–2036).
- 2025 Follicular Lymphoma Market Size: USD 1702 million in 2025
- 2036 Projected Malignant Pleural Effusion Market Size: USD 3081 million in 2036
- Growth Rate (2026-2036): 6.8 % CAGR
- Largest Malignant Pleural Effusion Market: United States
The Follicular Lymphoma Market Report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM Follicular Lymphoma Market Size from 2022 to 2036. The report also covers Follicular Lymphoma Treatment practices and unmet medical needs to curate the best opportunities and assess the market’s potential.
Key Factors Driving the Follicular Lymphoma Market
Follicular Lymphoma incidence fueling market growth
Follicular Lymphoma, the most common indolent NHL subtype, accounts for about 20–22% of cases. In 2024, an estimated 35K cases were diagnosed in the 7MM, with females higher at 18K. Cases are expected to rise by 2034 due to aging populations, better diagnostics, and longer survival, expanding the market and increasing demand for new treatments.
Follicular Lymphoma Follicular Lymphoma treatment paradigm
Current FL treatment mainly involves rituximab-based immunochemotherapy, radioimmunotherapy (e.g., ibritumomab tiuxetan), and targeted agents like PI3K inhibitors and CAR-T therapies in relapsed cases. Approved therapies include GAZYVA, TAZVERIK, EPKINLY/TEPKINLY, LUNSUMIO, YESCARTA, BREYANZI, KYMRIAH, BRUKINSA, ORDSPONO, and RITUXAN HYCELA.
Follicular Lymphoma pipeline spotlight
The Follicular Lymphoma pipeline is robust, featuring bispecific antibodies, next-generation ADCs, and off-the-shelf CAR constructs designed to achieve deeper, more durable remissions with better tolerability. Key pipeline therapies include MONJUVI, AZD0486, Golcadomide, Abexinostat, NKTR-255, CTX112, IMPT-314, and others. Leading companies driving these developments are Roche, Gilead/Kite, Novartis, AstraZeneca, BeiGene, Regeneron, and MEI Pharma. In January 2025, CRISPR Therapeutics announced plans to engage regulators on CTX112 for B-cell malignancies, with updates expected mid-2025. These advances build upon established treatments that define the current standard of care.
Follicular Lymphoma Market Dynamics and Opportunity
Adoption of newer therapies will hinge on demonstrating superior survival and quality-of-life benefits versus standard immunochemotherapy, balanced against cost, toxicity profile, and payer restrictions—defining the competitive commercial outlook of the Follicular Lymphoma market.
Follicular Lymphoma Disease Understanding
Follicular Lymphoma Overview
Follicular lymphoma is usually a slow-growing, indolent B-cell lymphoproliferative disorder that originates from transformed follicular center B cells. It often presents with widespread lymph node enlargement, bone marrow involvement, and an enlarged spleen, while involvement of organs outside the lymphatic system is less frequent. Low blood cell counts are relatively common, but systemic symptoms such as fever, night sweats, and weight loss are rare unless the disease transforms into diffuse large B-cell lymphoma. Follicular lymphoma is generally considered a chronic condition rather than a curable one.
Further details are provided in the report…
Follicular Lymphoma Diagnosis
The diagnosis of follicular lymphoma relies on examining tissue obtained from a lymph node or other affected site. An incisional biopsy is generally preferred over a needle biopsy to ensure enough tissue is available for grading and evaluating potential transformation. Immunohistochemical analysis typically shows positive staining for cell surface markers CD19, CD20, CD10, and monoclonal immunoglobulin, along with cytoplasmic bcl-2 protein. Most cases also exhibit the t(14;18) chromosomal translocation involving the IgH and bcl-2 genes. Imaging with CT scans of the chest, abdomen, and pelvis can identify abdominal or pelvic lymph node involvement, while PET scans may be helpful in selected scenarios, such as localized disease or suspected transformation. Bone marrow aspiration and chromosomal analysis can further support the diagnosis, as the t(14;18) translocation is present in the majority of patients with follicular lymphoma.
Further details related to country-based variations are provided in the report…
Follicular Lymphoma Treatment
Treatment approaches for follicular lymphoma depend on the disease stage. For patients who are asymptomatic with low tumor burden and no cytopenias, a “watch and wait” strategy is often appropriate, as early intervention with chemotherapy or single-agent rituximab has not shown an overall survival benefit. Patients who require treatment are generally managed with chemoimmunotherapy, which has been shown to improve response rates, response duration, and overall survival. Maintenance therapy with rituximab has demonstrated additional advantages in randomized trials. In front-line settings, lenalidomide was found to be non-inferior to chemoimmunotherapy and, in relapsed cases, combining lenalidomide with rituximab outperformed rituximab alone. Other options for relapsed disease include kinase inhibitors, stem cell transplantation (SCT), and chimeric antigen receptor T-cell (CAR-T) therapy. For early-stage, localized disease, radiation therapy or surgical excision may be considered in select patients.
Follicular Lymphoma Epidemiology
The Follicular Lymphoma epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Incidence Cases, Gender-specific Cases, Age-specific Cases, Stage Specific Cases, Grade Specific Cases, and Treated Cases by Line of therapy of Follicular lymphoma in the United States, EU4 countries (Germany, France, Italy, Spain) and the United Kingdom, and Japan from 2022 to 2036.
Key Findings from Follicular Lymphoma Epidemiological Analyses and Forecast
- Among the 7MM, the United States accounted for the highest number of cases of Follicular Lymphoma in 2024, with nearly 17,000 cases. These cases are anticipated to increase by 2034.
- In 2024, the highest incidence of follicular lymphoma was observed in the 60–80 age group with ~9000 cases, followed by individuals aged 40–59 with ~4000 cases.
- In 2024, stage IV specific cases of follicular lymphoma made up around 35% of the total cases.
- The incidence of follicular lymphoma in the EU4 and the UK was ~14,000 in 2024, with Germany having the highest cases.
- Total Diagnosed Incidence Cases
- Gender-specific Cases
- Age-specific Cases
- Stage Specific Cases
- Grade Specific Cases
- Treated Cases by Line of therapy
A few key players are leading the treatment landscape of Follicular Lymphoma, such as Incyte Corporation, AstraZeneca, Bristol Myers Squibb, Xynomic Pharmaceuticals, and others. The details of the country-wise and therapy-wise market size have been provided below.
- In the 7MM, the United States accounted for the highest market share, i.e. more than 65% in 2024, followed by France and Germany.
- The United States generated a revenue of approximately USD 1,000 million in 2024.
- Among the EU4 and the UK, Germany accounted for the highest market size in 2024 with approximately USD 100 million.
- Spain accounted for the least market size, approximately USD 60 million, among the EU4 and the UK in 2024.
The section dedicated to drugs in the Follicular Lymphoma report provides an in-depth evaluation of late-stage pipeline drugs (Phase III) related to Follicular Lymphoma. The drug chapters section provides valuable information on various aspects related to clinical trials of Follicular Lymphoma, such as the pharmacological mechanisms of the drugs involved, designations, approval status, patent information, and a comprehensive analysis of the pros and cons associated with each drug. Furthermore, it presents the most recent news updates and press releases on drugs targeting Follicular Lymphoma.
Follicular Lymphoma Marketed Drugs
LUNSUMIO (mosunetuzumab): Roche
LUNSUMIO (mosunetuzumab) is a bispecific antibody therapy developed for adults with relapsed or refractory (R/R) follicular lymphoma who have undergone two or more previous treatments. It functions by binding simultaneously to T cells and B cells, triggering the immune system to attack and eliminate cancerous B cells. However, it may also impact healthy cells. The most notable risk is Cytokine Release Syndrome (CRS), a potentially serious and life-threatening side effect. Its safety and effectiveness in children have not been established.
In December 2024, Chugai received regulatory approval in Japan for intravenous administration of LUNSUMIO, allowing its use as monotherapy for patients who have received at least two prior therapies—a key step forward in treating R/R follicular lymphoma. Previously, in December 2022, the FDA granted accelerated approval for LUNSUMIO in adults with R/R follicular lymphoma after two or more systemic therapies. Additionally, in June 2022, Roche announced that the European Commission granted conditional marketing authorization for LUNSUMIO to treat adults with R/R follicular lymphoma who had previously received at least two systemic therapies.
BRUKINSA (zanubrutinib): BeiGene
BRUKINSA (zanubrutinib) is a small-molecule Bruton's tyrosine kinase (BTK) inhibitor approved for use in adult patients with relapsed or refractory (r/r) follicular lymphoma, in combination with obinutuzumab, following two or more prior systemic therapies. It is the first and only BTK inhibitor specifically approved for follicular lymphoma. Zanubrutinib works by irreversibly binding to BTK, blocking B-cell signaling pathways that drive B-cell proliferation, adhesion, and migration, thereby helping to slow tumor growth.
In March 2024, the FDA granted accelerated approval for BRUKINSA with obinutuzumab for adults with r/r follicular lymphoma after at least two prior systemic treatments. Earlier, in August 2022, the drug received orphan-drug designation from the FDA for the treatment of follicular lymphoma.
Follicular Lymphoma Emerging Therapies
MONJUVI (tafasitamab): Incyte Corporation
MONJUVI (tafasitamab) is a humanized, Fc-engineered monoclonal antibody that targets CD19 on B-cells. By binding to CD19, it inhibits its function and induces B-cell destruction. In 2010, MorphoSys obtained exclusive global rights to develop and commercialize tafasitamab from Xencor, Inc. The antibody’s XmAb-modified Fc domain promotes B-cell killing through apoptosis and immune-mediated mechanisms, including Antibody-Dependent Cell-mediated Cytotoxicity (ADCC) and Antibody-Dependent Cellular Phagocytosis (ADCP).
In December 2024, Incyte presented late-breaking results at the ASH Annual Meeting from the pivotal Phase III inMIND trial. The study showed that MONJUVI (tafasitamab), when combined with lenalidomide and rituximab, significantly improved progression-free survival (PFS) in patients with relapsed or refractory follicular lymphoma, achieving both the primary endpoint of PFS and key secondary endpoints.
AZD0486: AstraZeneca
AZD0486 (previously TNB-486) is a novel, fully human IgG4 CD19xCD3 bispecific T-cell engager (TCE) that features a unique low-affinity anti-CD3 component designed to minimize cytokine release while maintaining strong T-cell–mediated killing of malignant B cells. Its silenced Fc region prevents nonspecific binding and antibody-dependent cellular cytotoxicity, and provides a long half-life that supports intermittent dosing. The drug is currently in Phase III development for treating follicular lymphoma.
In November 2024, at ASH 2024, AstraZeneca showcased the strength of its hematology portfolio with two oral presentations on AZD0486. Phase I data demonstrated encouraging efficacy in patients with relapsed/refractory follicular lymphoma, showing a 96% overall response rate (ORR) and 85% complete response rate (CRR) at doses of 2.4 mg and higher.
Follicular Lymphoma Market Outlook
Frontline treatment for follicular lymphoma is well established, with most patients achieving durable responses to chemoimmunotherapy (CIT). For localized disease, radiotherapy (RT) alone or combined with immunochemotherapy is commonly used, and RT alone may also be appropriate for relapsed localized cases.
The treatment landscape for follicular lymphoma is diverse and continues to evolve, offering multiple options for both frontline and relapsed/refractory (R/R) disease. Among the cornerstone therapies is GAZYVA/GAZYVARO (obinutuzumab), which, when combined with chemotherapy, has become a standard in frontline management and demonstrates efficacy in both untreated and relapsed patients. Similarly, RITUXAN (rituximab) and its combination form RITUXAN HYCELA remain widely used, particularly in relapsed cases. The availability of generic rituximab has further enhanced accessibility and cost-effectiveness, maintaining its key role in treatment.
Targeted therapies are also expanding options. TAZVERIK (tazemetostat), an EZH2 inhibitor, offers a precision medicine approach for patients with specific mutations, while BRUKINSA (ibrutinib), a Bruton's tyrosine kinase inhibitor, contributes to therapy in selected follicular lymphoma cases. The recent approvals of EPKINLY/TEPKINLY (epcoritamab), a bispecific antibody targeting CD3 and CD20, alongside CAR T-cell therapies including KYMRIAH (tisagenlecleucel), LUNSUMIO (mosunetuzumab), YESCARTA (axicabtagene ciloleucel), and BREYANZI (lisocabtagene maraleucel), are ushering in a new era of immunotherapy. These innovative treatments are demonstrating promising results, particularly in R/R disease, and have the potential to provide longer-lasting remissions.
Overall, a wide range of effective therapies is already available for follicular lymphoma, with ongoing research likely to introduce further advancements. During the 2026–2036 forecast period, emerging treatments are expected to enhance existing options, while rising global healthcare spending may improve access to more effective and affordable therapies for patients.
Latest KOL Views on Follicular Lymphoma
To stay abreast of the latest trends in the market, we conduct primary research by seeking the opinions of Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) who work in the relevant field. This helps us fill any gaps in data and validate our secondary research.
We have reached out to industry experts to gather insights on various aspects of Follicular Lymphoma, including the evolving treatment landscape, patients’ reliance on conventional therapies, their acceptance of therapy switching, drug uptake, and challenges related to accessibility. The experts we contacted included medical/scientific writers, professors, and researchers from prestigious universities in the US, Europe, the UK, and Japan.
Our team of analysts at Delveinsight connected with more than 15 KOLs across the 7MM. We contacted institutions. By obtaining the opinions of these experts, we gained a better understanding of the current and emerging treatment patterns in the Follicular Lymphoma market, which will assist our clients in analyzing the overall epidemiology and market scenario.
Follicular Lymphoma Report Qualitative Analysis
We perform Qualitative and Market Intelligence analysis using various approaches, such as SWOT analysis and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst’s discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.
Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, designation, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy. In efficacy, the trial’s primary and secondary outcome measures are evaluated; for instance, in trials for Follicular Lymphoma, one of the most important primary endpoints was achieving Maximum tolerated dose, PFS, Incidence of AEs, OR, and others.
Further, the therapies’ safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.
Follicular Lymphoma Market Access and Reimbursement
Follicular lymphoma, also known as follicle center lymphoma or nodular lymphoma, is a common type of non-Hodgkin’s lymphoma, a slow-growing cancer, which affects the body’s immune system. It may appear in your lymph nodes, bone marrow, or other organs. In January 2024, the PAN Foundation announced to opening of a new follicular lymphoma fund, providing up to USD 4,600 per year to help eligible patients pay for out-of-pocket deductible, copay, and coinsurance costs.
The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.
Follicular Lymphoma Market Report Insights
- Patient Population
- Therapeutic Approaches
- Follicular Lymphoma Market Size and Trends
- Existing Market Opportunity
- 11-year Forecast
- The 7MM Coverage
- Follicular Lymphoma Epidemiology Segmentation
- Key Cross Competition
- Current Treatment Practices
- Reimbursements
- Market Attractiveness
- Qualitative Analysis (SWOT, Conjoint Analysis, Unmet needs)
- Would there be any changes observed in the current treatment approach?
- Will there be any improvements in Follicular Lymphoma management recommendations?
- Would research and development advances pave the way for future tests and therapies for Follicular Lymphoma?
- Would the diagnostic testing space experience a significant impact and lead to a positive shift in the treatment landscape of Follicular Lymphoma?
- What kind of uptake will the new therapies witness in the coming years in Follicular Lymphoma patients?
Follicular Lymphoma Market Report Key Strengths
Follicular Lymphoma Market Report Assessment
Key Questions Answered in the Follicular Lymphoma Market Report
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
Table of Contents
200 Pages
- 1. Key Insights
- 2. Report Introduction
- 3. Follicular Lymphoma Market Overview at a Glance
- 3.1. Market Share (%) Distribution of Follicular Lymphoma by Country in 2025 in the 7MM
- 3.2. Market Share (%) Distribution of Follicular Lymphoma by Country in 2036 in the 7MM
- 4. Methodology
- 5. Executive Summary
- 6. Key Events
- 7. Disease Background and Overview
- 7.1. Introduction
- 7.2. Types of Follicular Lymphoma
- 7.2.1. In-situ Follicular B-cell Neoplasm
- 7.2.2. Follicular Lymphoma With Unusual Cytologic Features
- 7.2.3. Pediatric-type Follicular Lymphoma
- 7.2.4. Duodenal-type Follicular Lymphoma
- 7.2.5. Primary Cutaneous Follicle Center Lymphoma
- 7.3. Causes
- 7.4. Lifestyle Factors
- 7.4.1. Environmental Factors
- 7.4.2. Other Medical Conditions
- 7.5. Symptoms
- 7.6. Clinical Presentation
- 7.6.1. Staging of Follicular Lymphoma
- 7.6.2. Grading of Follicular Lymphoma
- 7.7. Etiopathogenesis
- 7.7.1. Bone Marrow Events
- 7.7.2. Germinal Center Events
- 7.7.3. Post-Germinal Center Events
- 7.8. Diagnosis
- 7.8.1. Blood Tests
- 7.8.2. Biopsy
- 7.8.3. Test to Diagnose Follicular Lymphoma
- 7.8.4. Diagnostic Guideline of Follicular Lymphoma
- 7.8.5. European Society for Medical Oncology Clinical Practice Guidelines for Diagnosis
- 7.9. Differential Diagnosis
- 7.9.1. Reactive Follicular Hyperplasia
- 7.9.2. Progressive Transformation of Germinal Centers
- 7.9.3. Castleman Disease, Hyaline Vascular Variant
- 7.9.4. Nodular Lymphocyte-Predominant Hodgkin Lymphoma
- 7.9.5. Lymphocyte-Rich Classic Hodgkin Lymphoma
- 7.9.6. Mantle Cell Lymphoma
- 7.9.7. Nodal Marginal Zone Lymphoma
- 7.10. Diagnostic Algorithm of Follicular Lymphoma
- 8. Treatment of Follicular Lymphoma
- 8.1. Initial Therapy for Early Stage Follicular Lymphoma
- 8.2. Initial Therapy for Advanced-stage Follicular Lymphoma
- 8.3. Treatment of Relapsed Follicular Lymphoma
- 8.4. Suggested Treatment Regimens in 2025 by NCCN (National Comprehensive Cancer Network)
- 8.5. Treatment Algorithm of Follicular Lymphoma
- 8.6. Treatment Guidelines for Follicular Lymphoma
- 8.6.1. Recommendation by the British Journal of Haematology
- 8.6.2. Guidelines by NCCN (National Comprehensive Cancer Network)
- 8.6.3. Guidelines by ESMO (European Society for Medical Oncology)
- 8.6.4. Guidelines by NICE (National Institute for Health and Care Excellence)
- 9. Epidemiology and Patient Population
- 9.1. Key Findings
- 9.2. Assumptions and Rationale
- 9.2.1. The United States
- 9.2.2. The Europe
- 9.2.3. Japan
- 9.3. Total Diagnosed Incidence Cases of Follicular Lymphoma in the 7MM
- 9.4. The United States
- 9.4.1. Total Diagnosed Incidence Cases of Follicular Lymphoma in the United States
- 9.4.2. Gender-specific Cases of Follicular Lymphoma in the United States
- 9.4.3. Age-specific cases of Follicular Lymphoma in the United States
- 9.4.4. Stage-specific Cases of Follicular Lymphoma in the United States
- 9.4.5. Grade-specific Cases of Follicular Lymphoma in the United States
- 9.4.6. Treated Case by Line of therapy of Follicular lymphoma in the United States
- 9.5. EU4 and the UK
- 9.5.1. Total Diagnosed Incidence Cases of Follicular Lymphoma in EU4 and the UK
- 9.5.2. Gender-specific Cases of Follicular Lymphoma in EU4 and the UK
- 9.5.3. Age-specific cases of Follicular Lymphoma in EU4 and the UK
- 9.5.4. Stage-specific Cases of Follicular Lymphoma in EU4 and the UK
- 9.5.5. Grade-specific Cases of Follicular Lymphoma in EU4 and the UK
- 9.5.6. Treated Case by Line of therapy of Follicular lymphoma in EU4 and the UK
- 9.6. Japan
- 9.6.1. Total Diagnosed Incidence Cases of Follicular Lymphoma in Japan
- 9.6.2. Gender-specific Cases of Follicular Lymphoma in Japan
- 9.6.3. Age-specific cases of Follicular Lymphoma in Japan
- 9.6.4. Stage-specific Cases of Follicular Lymphoma in Japan
- 9.6.5. Grade-specific Cases of Follicular Lymphoma in Japan
- 9.6.6. Treated Case by Line of therapy of Follicular lymphoma in Japan
- 10. Patient Journey
- 11. Marketed Therapies
- 11.1. Key Cross Competition
- 11.2. RITUXAN HYCELA: Genentech
- 11.2.1. Product Description
- 11.2.2. Regulatory Milestones
- 11.2.3. Other Developmental Activities
- 11.2.4. Clinical Development
- 11.2.5. Safety and Efficacy
- 11.3. BREYANZI (lisocabtagene maraleucel): Bristol Myers Squibb
- 11.3.1. Product Description
- 11.3.2. Regulatory Milestones
- 11.3.3. Clinical Development
- 11.3.4. Safety and Efficacy
- 11.4. YESCARTA (axicabtagene ciloleucel): Kite Pharma
- 11.4.1. Product Description
- 11.4.2. Regulatory Milestones
- 11.4.3. Other Developmental Activities
- 11.4.4. Clinical Developmental Activities
- 11.4.5. Safety and Efficacy
- 11.5. KYMRIAH (tisagenlecleucel): Novartis
- 11.5.1. Product Description
- 11.5.2. Regulatory Milestones
- 11.5.3. Other Developmental Activities
- 11.5.4. Clinical Developmental Activities
- 11.5.5. Safety and Efficacy
- 11.6. LUNSUMIO (mosunetuzumab): Roche
- 11.6.1. Product Description
- 11.6.2. Regulatory Milestones
- 11.6.3. Other Developmental Activities
- 11.6.4. Clinical Developmental Activities
- 11.6.5. Safety and Efficacy
- 11.7. EPKINLY/TEPKINLY (epcoritamab): Genmab/AbbVie
- 11.7.1. Product Description
- 11.7.2. Regulatory Milestones
- 11.7.3. Other Developmental Activities
- 11.7.4. Clinical Developmental Activities
- 11.7.5. Safety and Efficacy
- 11.8. TAZVERIK (tazemetostat): Ipsen/Eisai
- 11.8.1. Product Description
- 11.8.2. Regulatory Milestones
- 11.8.3. Other Developmental Activities
- 11.8.4. Clinical Developmental Activities
- 11.8.5. Safety and Efficacy
- 11.9. GAZYVA/ GAZYVARO (obinutuzumab): Roche
- 11.9.1. Product Description
- 11.9.2. Regulatory Milestones
- 11.9.3. Other Development Activities
- 11.9.4. Clinical Developmental Activities
- 11.9.5. Safety and Efficacy
- 11.10. BRUKINSA (zanubrutinib): BeiGene
- 11.10.1. Product Description
- 11.10.2. Regulatory Milestones
- 11.10.3. Other Developmental Activities
- 11.10.4. Clinical Developmental Activities
- 11.10.5. Safety and Efficacy
- 11.11. ORDSPONO (odronextamab): Regeneron Pharmaceuticals
- 11.11.1. Product Description
- 11.11.2. Regulatory Milestones
- 11.11.3. Other Developmental Activities
- 11.11.4. Clinical Developmental Activities
- 11.11.5. Safety and Efficacy
- 12. Emerging Therapies
- 12.1. Key Cross Competition
- 12.2. Zilovertamab Vedotin: Merck Sharp and Dohme
- 12.2.1. Product Description
- 12.2.2. Other Developmental Activities
- 12.2.3. Clinical Developmental Activities
- 12.2.4. Safety and Efficacy
- 12.2.5. Analyst View
- 12.3. CALQUENCE (Acalabrutinib): AstraZeneca
- 12.3.1. Product Description
- 12.3.2. Other Developmental Activities
- 12.3.3. Clinical Developmental Activities
- 12.3.4. Safety and Efficacy
- 12.3.5. Analyst View
- 12.4. CTX112: CRISPR Therapeutics
- 12.4.1. Product Description
- 12.4.2. Other Developmental Activities
- 12.4.3. Clinical Developmental Activities
- 12.4.4. Safety and Efficacy
- 12.4.5. Analyst View
- 12.5. BGB-16673: BeiGene
- 12.5.1. Product Description
- 12.5.2. Other Developmental Activities
- 12.5.3. Clinical Developmental Activities
- 12.5.4. Safety and Efficacy
- 12.5.5. Analyst View
- 12.6. NKTR-255: Nektar Therapeutics
- 12.6.1. Product Description
- 12.6.2. Other Developmental Activities
- 12.6.3. Clinical Developmental Activities
- 12.6.4. Safety and Efficacy
- 12.6.5. Analyst View
- 12.7. NVG-111: NovalGen
- 12.7.1. Product Description
- 12.7.2. Other Developmental Activities
- 12.7.3. Clinical Developmental Activities
- 12.7.4. Safety and Efficacy
- 12.7.5. Analyst View
- 12.8. AS-1763 (docirbrutinib): Carna Biosciences
- 12.8.1. Product Description
- 12.8.2. Other Developmental Activities
- 12.8.3. Clinical Developmental Activities
- 12.8.4. Safety and Efficacy
- 12.8.5. Analyst View
- 12.9. Cemacabtagene Ansegedleucel (ALLO-501): Allogene Therapeutics
- 12.9.1. Product Description
- 12.9.2. Other Developmental Activities
- 12.9.3. Clinical Developmental Activities
- 12.9.4. Safety and Efficacy
- 12.9.5. Analyst View
- 12.10. Abexinostat: Xynomic Pharmaceuticals
- 12.10.1. Product Description
- 12.10.2. Other Developmental Activities
- 12.10.3. Clinical Developmental Activities
- 12.10.4. Safety and Efficacy
- 12.10.5. Analyst View
- 12.11. Golcadomide: Bristol-Myers Squibb
- 12.11.1. Product Description
- 12.11.2. Other Developmental Activities
- 12.11.3. Clinical Developmental Activities
- 12.11.4. Safety and Efficacy
- 12.11.5. Analyst View
- 12.12. MONJUVI (tafasitamab): Incyte Corporation
- 12.12.1. Product Description
- 12.12.2. Other Developmental Activities
- 12.12.3. Clinical Developmental Activities
- 12.12.4. Safety and Efficacy
- 12.12.5. Analyst View
- 12.13. AZD0486: AstraZeneca
- 12.13.1. Product Description
- 12.13.2. Other Developmental Activities
- 12.13.3. Clinical Developmental Activities
- 12.13.4. Safety and Efficacy
- 12.13.5. Analyst View
- 13. Follicular Lymphoma: Seven Major Market Analysis
- 13.1. Key Findings
- 13.2. Market Outlook
- 13.3. Conjoint Analysis
- 13.4. Key Market Forecast Assumptions
- 13.4.1. Cost Assumptions and Rebate
- 13.4.2. Pricing Trends
- 13.4.3. Analogue Assessment
- 13.4.4. Launch Year and Therapy Uptake
- 13.5. Market Size of Follicular Lymphoma in the 7MM
- 13.6. The United States
- 13.6.1. Total Market Size of Follicular Lymphoma in the United States
- 13.6.2. Market Size of Follicular Lymphoma by Therapies in the United States
- 13.7. EU4 and the UK
- 13.7.1. Total Market Size of Follicular Lymphoma in EU4 and the UK
- 13.7.2. Market Size of Follicular Lymphoma by Therapies in EU4 and the UK
- 13.8. Japan
- 13.8.1. Total Market Size of Follicular Lymphoma in Japan
- 13.8.2. Market Size of Follicular Lymphoma by Therapies in Japan
- 14. KOL Views
- 15. SWOT Analysis
- 16. Unmet Needs
- 17. Market Access and Reimbursement
- 17.1. United States
- 17.1.1. Centre for Medicare and Medicaid Services (CMS)
- 17.2. EU4 and the UK
- 17.2.1. Germany
- 17.2.2. France
- 17.2.3. Italy
- 17.2.4. Spain
- 17.2.5. United Kingdom
- 17.3. Japan
- 17.3.1. MHLW
- 17.4. Reimbursement Scenario in Follicular Lymphoma
- 17.4.1. United States
- 17.4.2. Europe
- 17.4.3. Japan
- 18. Appendix
- 18.1. Bibliography
- 18.2. Report Methodology
- 19. DelveInsight Capabilities
- 20. Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.